by Jad Duncan | May 9, 2022 | News
The use of protein degraders is a promising area of emerging small molecule therapies. Rather than inhibit disease-causing proteins, degraders use a natural cellular process to break them down. Origami Therapeutics is using its proprietary drug discovery platform to...
by Jad Duncan | Apr 1, 2022 | News
Protein degradation is an up-and-coming approach that most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. Read full...
by Jad Duncan | Mar 21, 2022 | News
Beth Hoffman is Founder, President, & CEO @ Origami Therapeutics. She brings more than 25 years experience of CNS drug discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain, and...
by Jad Duncan | Mar 16, 2022 | News
Listen to the...
by Jad Duncan | Mar 16, 2022 | News
Oral drugs to halt neurodegeneration Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our...
by Jad Duncan | Mar 8, 2022 | News
28 Feb – 3 March, 2022 Presenting at 17th Annual Huntington’s Disease Therapeutics Conference https://web.cvent.com/event/a0991146-7ae2-4f10-bc6c-0bf856caac34/summary 28-30 March, 2022 Presenting at 10th Annual Neurodegenerative Drug Development Summit About...
